{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:38:34Z","timestamp":1786451914087,"version":"build-2736575974"},"reference-count":104,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Primary bone sarcomas are rare, heterogeneous malignancies with limited therapeutic options, particularly in metastatic disease where outcomes remain poor. This study synthesizes current literature to evaluate emerging therapeutic strategies and biological determinants of response across osteosarcoma, Ewing sarcoma, and chondrosarcoma, as presented at the ESMO Annual Meeting, 2025. Key approaches reviewed include VEGFR-targeted tyrosine kinase inhibitors (TKIs), DNA damage response (DDR) inhibition, MYC targeting, immune checkpoint inhibitors (ICIs), and surfaceome-directed therapies such as antibody\u2013drug conjugates (ADCs) and chimeric antigen receptor T cell therapy. Across studies, TKIs demonstrated short lasting activity as monotherapy but improved outcomes in some of the studies when combined with ICIs or chemotherapy, reflecting their role in remodeling the tumor microenvironment (TME); importantly, controlled studies with TKI and chemotherapy upfront are ongoing. DDR- and MYC-targeted therapies have shown strong preclinical rationale but limited clinical efficacy, highlighting challenges in translation. Immune-based therapies exhibited variable responses, with dedifferentiated chondrosarcoma (DDCS) emerging as a responsive histotype. Surfaceome-targeting strategies, particularly ADCs, demonstrated promising early clinical activity. Overall, bone sarcoma rarity, tumor heterogeneity, immunosuppressive TME, and lack of predictive factors challenge drug discovery for bone sarcoma patients. These findings underscore the importance of combination strategies and biomarker-driven patient selection and suggest that continued integration of targeted and immunotherapeutic approaches will be critical to improving outcomes in bone sarcoma.<\/jats:p>","DOI":"10.3390\/biom16081167","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:51:36Z","timestamp":1786449096000},"page":"1167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting"],"prefix":"10.3390","volume":"16","author":[{"given":"Samhita","family":"Kotapati","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakkshy","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-6705","authenticated-orcid":false,"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33125, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref_1","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2026, April 18). SEER Cancer Stat Facts: Bone and Joint Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/bones.html."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Palmerini, E., Righi, A., and Staals, E.L. (2020). Rare Primary Malignant Bone Sarcomas. Cancers, 12.","DOI":"10.3390\/cancers12113092"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO-25-00210","article-title":"Is there a role for mifamurtide in nonmetastatic high-grade osteosarcoma? Results from the Italian Sarcoma Group (ISG\/OS-2) and Spanish Sarcoma Group (GEIS-33) trials","volume":"43","author":"Palmerini","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.suronc.2018.05.009","article-title":"Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas","volume":"27","author":"Ho","year":"2018","journal-title":"Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.21.01942","article-title":"High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (metastatic) Ewing sarcoma","volume":"40","author":"Koch","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/ijc.70023","article-title":"Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade","volume":"157","author":"Ducrot","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1038\/s41467-025-58678-6","article-title":"Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes","volume":"16","author":"Soupir","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1158\/1078-0432.CCR-25-0649","article-title":"Tumor immune microenvironment\u2013associated prognostic and mifamurtide-response gene signatures for localized osteosarcoma: A correlative study of the ISG\/OS-2 trial","volume":"31","author":"Palmerini","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fleuren, E.D.G., Vlenterie, M., and van der Graaf, W.T.A. (2023). Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1013359"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: A non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/0284186X.2018.1503714","article-title":"Pazopanib in relapsed osteosarcoma patients: Report on 15 cases","volume":"58","author":"Longhi","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase II clinical trial","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): A multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e23540","DOI":"10.1200\/JCO.2023.41.16_suppl.e23540","article-title":"A phase II study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy","volume":"41","author":"Zhang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"508-16","DOI":"10.1093\/annonc\/mdr151","article-title":"Phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An italian sarcoma group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"v688","DOI":"10.1093\/annonc\/mdz283.009","article-title":"Phase I combination dose-finding\/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients aged 2 to\u226425 years with relapsed\/refractory osteosarcoma","volume":"30","author":"Gaspar","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1200\/JCO.2025.43.16_suppl.11510","article-title":"Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R\/DDRs\/VEGFR2, in relapsed or refractory osteosarcoma","volume":"43","author":"Ye","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1200\/JCO.2024.42.16_suppl.11539","article-title":"Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liao, S., Li, J., Gao, S., Han, Y., Han, X., Wu, Y., Bi, J., Xu, M., and Bi, W. (2023). Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1158857"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"TPS3177","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3177","article-title":"Phase 1 study of C019199, an oral CSF-1R\/DDRs\/VEGFR2 multiple kinase inhibitor, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including tenosynovial giant cell tumor","volume":"40","author":"Shen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jamaoncol.2024.4381","article-title":"Lenvatinib plus ifosfamide and etoposide in children and young adults with relapsed osteosarcoma: A phase 2 randomized clinical trial","volume":"10","author":"Gaspar","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1038\/s41467-025-65467-8","article-title":"Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE\/PKUPH-Sarcoma 11): A randomized phase II study","volume":"16","author":"Xie","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","article-title":"Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine","volume":"12","author":"Kwilas","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/jco.2014.32.15_suppl.4501","article-title":"Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma","volume":"32","author":"Apolo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_31","unstructured":"National Cancer Institute (NCI) (2026, April 18). A Feasibility and Randomized Phase 2\/3 Study of the VEGFR2\/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma. ClinicalTrials.gov Identifier: NCT05691478, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05691478."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e71044","DOI":"10.1002\/cam4.71044","article-title":"Prognostic factors in newly diagnosed high-grade osteosarcoma\u2014A systematic review","volume":"14","author":"Tirtei","year":"2025","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2025.43.16_suppl.10008","article-title":"Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study","volume":"43","author":"Berlanga","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/13543784.2024.2388571","article-title":"Zanzalintinib (XL092): A next-generation tyrosine kinase inhibitor\u2014Comprehensive review of early safety and efficacy data","volume":"33","author":"Yu","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_35","unstructured":"Livingston, J.A. (2026, April 30). A Phase 2 Trial of Zanzalintinib in Advanced\/Metastatic Bone Sarcomas (ZAMBONE). ClinicalTrials.gov Identifier: NCT07193550, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07193550."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104710","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1200\/JCO.2024.42.16_suppl.11525","article-title":"Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma","volume":"42","author":"Avutu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature25748","article-title":"EWS\u2013FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma","volume":"555","author":"Gorthi","year":"2018","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ccell.2017.12.009","article-title":"EWS\/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma","volume":"33","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1158\/1078-0432.CCR-17-1121","article-title":"Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma","volume":"23","author":"Heske","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): An open-label, phase 1b study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/cncr.33349","article-title":"SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma","volume":"127","author":"Chugh","year":"2021","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes. Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10005","DOI":"10.1200\/JCO.2025.43.16_suppl.10005","article-title":"Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma","volume":"43","author":"Forrest","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114201","DOI":"10.1016\/j.ejca.2024.114201","article-title":"Precision cancer medicine platform trials: Concepts and design of AcS\u00e9-ESMART","volume":"208","author":"Geoerger","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1200\/JCO.2023.41.16_suppl.10040","article-title":"Safety and PK (pharmacokinetic) profile of niraparib + dostarlimab in pediatric patients with recurrent or refractory solid tumors: SCOOP study","volume":"41","author":"Doz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","unstructured":"Choy, E. (2026, April 14). Phase I Study of Olaparib and Temozolomide for Ewing\u2019s Sarcoma or Rhabdomyosarcoma. ClinicalTrials.gov Identifier: NCT01858168, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01858168."},{"key":"ref_49","first-page":"638-e952","article-title":"Olaparib for childhood tumors harboring defects in DNA damage repair genes: Arm H of the NCI-COG Pediatric MATCH trial","volume":"29","author":"Pinkney","year":"2024","journal-title":"Oncologist"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","article-title":"A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies","volume":"137","author":"Federico","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1200\/JCO.2023.41.16_suppl.3073","article-title":"MYC amplification segment-size mutual exclusivity analysis with other oncogenic events in a pan-cancer sequencing cohort","volume":"41","author":"Repetto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1200\/JCO.2025.43.16_suppl.10045","article-title":"MYC amplification as a prognostic biomarker in osteosarcoma: A report from the Children\u2019s Oncology Group","volume":"43","author":"Whittle","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1200\/JCO.2025.43.16_suppl.10043","article-title":"MYC amplification and protein expression as prognostic markers in pediatric and young adult osteosarcoma","volume":"43","author":"Nagy","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_54","first-page":"e2400855","article-title":"Prognostic value of the G2 expression signature and MYC overexpression in childhood high-grade osteosarcoma","volume":"9","author":"Gaspar","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: A phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"key":"ref_56","unstructured":"Vall d\u2019Hebron Institute of Oncology (2026, April 15). A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the MYC Inhibitor OMO-103 Administered Intravenously in Patients with Advanced High-Grade Osteosarcoma (Osteomyc). ClinicalTrials.gov Identifier: NCT06650514, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06650514."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e35628","DOI":"10.1002\/cncr.35628","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial","volume":"131","author":"Palmerini","year":"2025","journal-title":"Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"11506","DOI":"10.1200\/JCO.2024.42.16_suppl.11506","article-title":"ImmunoSarc II master trial (phase II of sunitinib and nivolumab): Results from the dedifferentiated chondrosarcoma (DDCS) cohort\u2014A GEIS, ISG and UCL study","volume":"42","author":"Strauss","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.medj.2025.100809","article-title":"Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1002\/mog2.92","article-title":"Immunotherapy for gastric cancer: Advances and challenges","volume":"3","author":"Zhang","year":"2024","journal-title":"MedComm Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_62","unstructured":"Dela Cruz, F.S., Mauguen, A., Piracha, L., White, C., Manino, N., Poulcallec, C., Musleh, H., Navid, F., Gill, J.B., and Harrison, D.J. (2024, January 14). A multi-center phase II study of the anti-GD2 humanized monoclonal antibody naxitamab in combination with GM-CSF in recurrent osteosarcoma. Proceedings of the Connective Tissue Oncology Society (CTOS) Annual Meeting 2024, San Francisco, CA, USA. Available online: https:\/\/ctos2024.eventscribe.net\/fsPopup.asp?PresentationID=1491241&mode=presInfo."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e008744","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children\u2019s Oncology Group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., and Zhang, Y. (2013). B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070689"},{"key":"ref_66","unstructured":"Xie, L. (June, January 30). Tamronlimab pelunstide (tam-peli) in relapsed\/refractory Ewing sarcoma and chondrosarcoma: Results from the ARTEMIS-II study. Proceedings of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, USA."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e2500094","DOI":"10.1200\/OA-25-00094","article-title":"PEPN1924, a phase II study of trastuzumab deruxtecan in patients with recurrent human epidermal growth factor receptor 2+ osteosarcoma: A Children\u2019s Oncology Group Pediatric Early-Phase Clinical Trial Network study","volume":"2","author":"Reed","year":"2025","journal-title":"JCO Oncol. Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11507","DOI":"10.1200\/JCO.2024.42.16_suppl.11507","article-title":"ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma","volume":"42","author":"Xie","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S1337","DOI":"10.1016\/j.annonc.2025.08.3295","article-title":"ARTEMIS-002: A phase II study of HS-20093 in patients with relapsed or refractory sarcomas","volume":"36","author":"Xie","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_70","unstructured":"(2026, April 18). A Study of GSK5764227 in Participants with Advanced Solid Tumors (EMBOLD PanTumor-101). ClinicalTrials.gov Identifier: NCT06551142, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06551142."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody\u2013drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ben-Ami, E., Perret, R., Huang, Y., Courgeon, F., Gokhale, P.C., Laroche-Clary, A., Eschle, B.K., Velasco, V., Le Loarer, F., and Algeo, M.-P. (2020). LRRC15 targeting in soft-tissue sarcomas: Biological and clinical implications. Cancers, 12.","DOI":"10.3390\/cancers12030757"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"104404","DOI":"10.1016\/j.esmoop.2025.104404","article-title":"91P targeting leucine-rich repeat-containing protein 15 (LRRC15): SOT106 antibody-drug conjugate for soft tissue sarcoma and osteosarcoma therapy","volume":"10","author":"Jaburek","year":"2025","journal-title":"ESMO Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","article-title":"First-in-human phase I study of ABBV-085, an antibody\u2013drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors","volume":"27","author":"Demetri","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_75","unstructured":"Lu, X. (2025, April 22). Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-Cohort Exploratory Clinical Study. ClinicalTrials.gov Identifier: NCT06776198, Available online: https:\/\/clinicaltrials.gov\/s-tudy\/NCT06776198."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1002\/mog2.94","article-title":"Extracellular vesicles in cancer drug resistance: Mechanistic insights and therapeutic implications","volume":"3","author":"Zuo","year":"2024","journal-title":"MedComm Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1158\/1535-7163.MCT-25-0108","article-title":"Targeted delivery of a potent STING agonist payload via an antibody\u2013drug conjugate drives robust antitumor activity in preclinical models","volume":"25","author":"Gruber","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e15133","DOI":"10.1200\/JCO.2025.43.16_suppl.e15133","article-title":"LRRC15-radioimmunotheranostics: Targeting TGF\u03b2-driven resistance in immune-excluded solid tumors","volume":"43","author":"Ulmert","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: A phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Young, E.P., Johnson, C.A., Lee, A.G., Morris, D., Tsui, J., Breese, M.R., Camara Serrano, J.A., Schott, C.R., Abram, C.L., and Leung, S.G. (2025). STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcoma. bioRxiv.","DOI":"10.1101\/2025.10.24.684275"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: Results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2014.07.004","article-title":"Understanding and exploiting 5T4 oncofoetal glycoprotein expression","volume":"29","author":"Stern","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Southgate, T.D., McGinn, O.J., Castro, F.V., Rutkowski, A.J., Al-Muftah, M., Marinov, G., Smethurst, G.J., Shaw, D., Ward, C.M., and Miller, C.J. (2010). CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009982"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: An attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"TPS3164","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3164","article-title":"TUB-030, a novel ADC targeting 5T4: A phase I\/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors","volume":"43","author":"Sen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e15110","DOI":"10.1200\/JCO.2025.43.16_suppl.e15110","article-title":"ACR246, a first-in-class next-generation 5T4-ADC, as a potential choice of treating 5T4-positive solid tumors","volume":"43","author":"Jiao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","article-title":"Phase II trial of the glycoprotein non-metastatic B-targeted antibody\u2013drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children\u2019s Oncology Group","volume":"121","author":"Kopp","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.15698\/cst2025.08.311","article-title":"Datopotamab deruxtecan induces hallmarks of immunogenic cell death","volume":"9","author":"Forveille","year":"2025","journal-title":"Cell Stress"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Funasaka, C., Naito, Y., Kubota, H., Ishiguro, Y., Fuse, N., Wakabayashi, M., Sato, A., Yuda, J., Ishii, G., and Suzuki, T. (2025). Trial in progress: Phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr). Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1633324"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/2767-9764.CRC-25-0086","article-title":"Preclinical evaluation of folate receptor-\u03b1 chimeric antigen receptor T cells exhibits highly efficient antitumor activity against osteosarcoma","volume":"5","author":"Choe","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_91","unstructured":"Choe, M. (2026, April 15). Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Osteosarcoma, FIERCe Trial. Fred Hutchinson Cancer Center. Available online: https:\/\/www.fredhutch.org\/en\/research\/clinical-trials\/trial-details.html."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2022.40.16_suppl.2541","article-title":"STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent\/refractory solid tumors in children and young adults","volume":"40","author":"Albert","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_94","unstructured":"Baylor College of Medicine (2026, July 21). Phase I Study of Autologous T Lymphocytes Expressing GD2-Specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients with Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers (GAIL-N). ClinicalTrials.gov Identifier: NCT03635632, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03635632."},{"key":"ref_95","unstructured":"Bambino Ges\u00f9 Hospital and Research Institute (2026, July 21). Phase I\/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and\/or Relapsed\/Refractory Neuroblastoma or Other GD2-Positive Solid Tumors. ClinicalTrials.gov Identifier: NCT03373097, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03373097."},{"key":"ref_96","unstructured":"St. Jude Children\u2019s Research Hospital (2026, July 21). B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients with Solid Tumors (3CAR). ClinicalTrials.gov Identifier: NCT04897321, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04897321."},{"key":"ref_97","unstructured":"Ramakrishna, S. (2026, July 21). Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Children and Young Adults with Relapsed or Refractory Solid Tumor Expressing B7-H3 Target. ClinicalTrials.gov Identifier: NCT06500819, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06500819."},{"key":"ref_98","unstructured":"Livingston, J.A. (2026, July 21). A First-in-Human Phase 1 Trial of T Cell Membrane-Anchored Tumor Targeted IL12 (Attil12)-T Cell Therapy in Subjects with Advanced\/Metastatic Soft Tissue and Bone Sarcoma. ClinicalTrials.gov Identifier: NCT05621668, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05621668."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13046-015-0251-5","article-title":"EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance","volume":"34","author":"Sevelda","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-24-4128","article-title":"Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma","volume":"31","author":"Tap","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41467-026-68716-6","article-title":"Olutasidenib in recurrent\/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: Phase 1b\/2 trial","volume":"17","author":"Jones","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"TPS11582","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS11582","article-title":"Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER)","volume":"43","author":"Wagner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","article-title":"Preclinical characterization and phase I trial results of INBRX-109, a third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma","volume":"29","author":"Subbiah","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"TPS11582","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11582","article-title":"A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma","volume":"40","author":"Chawla","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:07:19Z","timestamp":1786450039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":104,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081167"],"URL":"https:\/\/doi.org\/10.3390\/biom16081167","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}